EO-S100850

GSK and iTeos Therapeutics have discontinued development of belrestotug, their TIGIT-targeting immunotherapy, after it failed to significantly delay tumor progression in non-small cell lung cancer patients.

Metsera's MET-097i, an ultra-long acting GLP-1 receptor agonist, showed substantial placebo-adjusted weight loss of up to 11.3% after 12 weeks in a Phase 2a trial.

Incyte has halted the development of zilurgisertib, an ALK2 inhibitor, due to limited efficacy observed in a Phase I trial for myelofibrosis-associated anemia and fibrodysplasia ossificans progressiva.

iTeos Therapeutics has deprioritized inupadenant for non-small cell lung cancer (NSCLC) treatment due to underwhelming Phase II trial results.

iTeos Therapeutics reported a 63.9% overall response rate (ORR) in a Phase 2 trial of inupadenant plus chemotherapy for metastatic non-small cell lung cancer (NSCLC).